Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)
Phase 3
Completed
- Conditions
- Metabolic SyndromeDyslipidemia
- Registration Number
- NCT00240266
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 15
Inclusion Criteria
- Signed informed consent
- males aged 45-65
- insulin resistance
- central obesity
- LDL-C <6 mmol/L
- plasma triglycerides >=1.7 and ≤5.5 mmol/L
- HDL-C ≤1.2 mmol/L.
Exclusion Criteria
- total cholesterol >7mmol/L
- pre-existing cardiovascular disease, diabetes, proteinuria or renal failure
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Determine the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.
- Secondary Outcome Measures
Name Time Method Determine the effect of treatment with rosuvastatin on: - plasma concentration of cholesterol ester transfer protein and capacity to transfer cholesterol from HDL-C to apoB-containing lipoproteins, one of the steps in RCT. - plasma concentration of preβ1-HDL. - cholesterol esterification by measuring plasma lecithin:cholesterol acyl transferase concentration and capacity to esterify cholesterol, one of the stops in RCT. - plasma concentration of LDL cholesterol, HDL-C and apoA-1.
Trial Locations
- Locations (1)
Research Site
🇦🇺Melbourne, Victoria, Australia